Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

  • Technology appraisal guidance
  • TA385
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the committee

A. The evidence review group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment (HTA) Group:

  • Scotland G, Javanbakht M, Scott N et al. Ezetimibe for treating primary (heterozygous‑familial and non‑familial) hypercholesterolaemia. Aberdeen HTA Group, August 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Merck Sharp & Dohme Ltd

II. Professional/expert and patient/carer groups:

  • HEART UK

  • British Heart Foundation

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Oxfordshire Clinical Commissioning Group

  • NHS West Essex Clinical Commissioning Group

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Aberdeen Health Technology Assessment Group

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on ezetimibe for treating primary heterozygous‑familial and non‑familial hypercholesterolaemia by attending the initial committee discussion and providing a written statement to the committee. They were also invited to comment on the ACD.

  • Dr Adie Viljoen, Chemical Pathologist, nominated by Merck Sharp & Dohme Ltd – clinical expert

  • Professor Anne-Marie Kelly, Consultant Chemical Pathologist, nominated by the Royal College of Pathologists – clinical expert

  • Stephen Boley, nominated by HEART UK – patient expert

E. Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • Merck Sharp & Dohme Ltd

ISBN: 978-1-4731-1706-8